ArticleJournal of magnetic resonance imaging : JMRI2025
The Diagnostic Value of Contrast-Enhanced Vessel Wall MRI for Diagnosing Neuropsychiatric Systemic Lupus Erythematosus.
Article in Journal of magnetic resonance imaging : JMRI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Meningovascular Inflammation in Cerebral Amyloid Angiopathy-Related Cortical Superficial Siderosis.Annals of clinical and translational neurology · 2026Article
- Enhanced Visualization of Intracranial Cortical Arteries Using Deep Learning Reconstruction in Vessel Wall MR Imaging.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Article
- The Diagnostic Value of Contrast-Enhanced Vessel Wall MRI for Diagnosing Neuropsychiatric Systemic Lupus Erythematosus.Journal of magnetic resonance imaging : JMRI · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundImaging biomarkers for neuropsychiatric systemic lupus erythematosus (NPSLE) are highly needed, and intracranial contrast-enhanced vessel wall imaging (CE-VWI) can potentially detect cerebral vessel wall abnormalities in lupus. PURPOSE: To evaluate the diagnostic value of CE-VWI in differentiating NPSLE from non-NPSLE. STUDY TYPE: Cross-sectional, retrospective. SUBJECTS: Forty-seven patients with NPSLE (mean age, 44.3 years ± 13.2 standard deviation [SD], 40 females, 85%) and 52 patients without NPSLE (mean age, 43.0 years ± 16.5 SD, 49 females, 89%). The non-NPSLE group consisted of SLE patients who had no NP symptoms or were diagnosed with comorbidities from other diseases. FIELD STRENGTH/SEQUENCE: 3-T, three-dimensional (3D) contrast-enhanced vessel wall imaging (3D-T1-CUBE). ASSESSMENT: Vessel wall lesions (VWLs) were visually assessed across 15 segments, from the internal carotid artery and basilar artery to A1-A2 for ACA, M1-M2 for MCA, and P1-P2 for PCA, for wall thickening and enhancement. Conventional MRI and MR angiography were also used to assess infarction, hemorrhage, atrophy, and arterial stenosis. STATISTICAL TESTS: Paired comparisons using the chi-square and unpaired t-tests were followed by multivariate logistic regression analysis incorporating factors with significant group differences to identify associations with NPSLE. Receiver operating characteristic (ROC) analysis with the area under the curve (AUC) assessed the diagnostic performance of CE-VWI. A p-value < 0.05 was considered statistically significant.
resultsThe NPSLE group showed a significantly higher number of contrast-enhancing VWLs (CE-VWLs; median [interquartile range]: 2 [0.5-4] vs. 0 [0-1]). Cerebral infarctions and arterial stenotic lesions were more common in NPSLE, occurring in 12 (26%) vs. 2 (3%) and 19 (40%) vs. 5 (9%) of patients, respectively. A multivariate logistic regression analysis identified CE-VWLs as the sole significant factor associated with NPSLE (odds ratio, 1.97; 95% confidence interval, 1.23-3.16). The ROC analysis showed an AUC of 0.78 for CE-VWLs, with a sensitivity of 60% and a specificity of 87%. DATA
conclusionCE-VWI may demonstrate high specificity and good diagnostic performance in differentiating NPSLE from non-NPSLE. EVIDENCE LEVEL: 3. TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.